{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016868","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.037892+00:00","generated_at":"2026-06-24T01:00:38.461538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nkarta Q2 net loss $27M; NKX101 AML 60% CR, NKX019 NHL 50% CR","bullets":["Q2 2022 net loss $27.0M ($0.61/share); cash & investments $415.0M, sufficient into 2025.","NKX101 Phase 1: 3/5 AML patients at higher dose achieved CR (60%); 2 of 3 MRD-negative.","NKX019 Phase 1: 3/6 NHL patients at higher dose achieved CR (50%); included DLBCL and MCL.","Raised ~$215.6M net from public offering in April 2022; lease amendments add $15M tenant improvements.","Promoted leaders: Dr. Brandenberger to CTO, Yvonne Li to CAO, Dr. Shook to VP Clinical Dev."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016868","json":"https://secwatch.observer/filing/0000950170-22-016868.json","markdown":"https://secwatch.observer/filing/0000950170-22-016868.md","text":"https://secwatch.observer/filing/0000950170-22-016868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022016868/0000950170-22-016868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022016868/nktx-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:00:38.461538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}